Anavex 7-1037 reduces rate of cancer tumor growth 69% in pre-clinical studies, compared to currently marketed drug Dacarbazine showing no measurabl...(gy (i.e. screening ofpotential candidate...)

ANAVEX 7-1037 has been previously reported to exhibit high affinity for sigma-1 (nanomolar) receptors and moderate (micromolar) affinity for sigma-2 receptors and sodium channels. In addition, ANAVEX 7-1037 has been shown to induce selective apoptosis (programmed cell death) in HCT116 colon cancer cells in vitro, as detailed in a press release dated December 11, 2007.

These features of ANAVEX 7-1037 have made it one of the company's lead compounds in its efforts to develop pioneering, new anti-cancer drugs for the treatment of solid tumors. ANAVEX 7-1037 has so far been tested in vitro against more than 20 human cancer cell lines representing different types of cancer - it has demonstrated significant in vitro tumor-growth-delaying activity against most of them, as represented by the GI50 (i.e. 50% of the dose required for tumor growth inhibition) of the compound. As such, ANAVEX 7-1037 has been advanced for testing against additional xenografts in order to further establish and confirm its potential as a potent anti-cancer drug.

ANAVEX 7-1037 is being studied for activity against a rare type of melanoma called clear cell sarcoma. Tests are performed by ANAVEX on xenografts developed directly from a sample that was surgically removed from a patient (primary/patient-derived xenografts) suffering from the disease. The patient had been treated with Dacarbazine. This study was implemented as a first step in ANAVEX's efforts to test the activity of the compound against melanoma, as the in-vitro results suggested that the compound may be selective against certain cancer types (such as melanoma, colon, breast and prostate).

Drugs that act on the underlying cause of the disease and/or slow/reverse the progression of the disease, which have a novel mode of action that could fulfill some
'/>"/>